Sanofi to Acquire Vicebio for $1.6 Billion

In a transformative acquisition, Sanofi has entered a definitive agreement to acquire Vicebio, a biopharmaceutical firm specializing in next-generation vaccine development, for up to $1.6 billion. The deal includes an upfront payment of $1.15 billion and milestone payments contingent on development and regulatory achievements. Vicebio's proprietary Molecular Clamp technology, invented at The University of Queensland, stabilizes viral glycoproteins, optimizing immune responses and facilitating the production of multivalent vaccines. Their lead product, VXB-241, is in Phase 1 clinical trials, targeting Respiratory Syncytial Virus and Human Metapneumovirus. Vicebio's creation was driven by Medicxi, and it benefited from investments from notable firms like TCGX, venBio Partners, and others. This acquisition allows Sanofi to access new vaccine technologies to deepen its pipeline and presence in the vaccine market, emphasizing its commitment to innovating medicines and vaccines for unmet medical needs.